Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budiodarone in Non-permanent Atrial Fibrillation
NCT07792239Phase 2Recruiting
- Sponsor
- XYRA LLC
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of budiodarone in Atrial fibrillation (AFib), sponsored by XYRA LLC. Primary endpoint: Proportion of participants that have no long episodes of atrial fibrillation (LEAF) in the final month of treatment at 24 weeks. Started Aug 2026; status: recruiting.
02
Drugs
budiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07792239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792239.